ValuEngine cut shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a report released on Friday.
A number of other research analysts have also recently commented on CLSN. Zacks Investment Research cut Celsion from a buy rating to a hold rating in a research note on Thursday, January 11th. Oppenheimer began coverage on Celsion in a research note on Tuesday, November 21st. They set an outperform rating and a $9.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Celsion currently has a consensus rating of Buy and an average price target of $11.90.
Celsion (NASDAQ:CLSN) opened at $2.35 on Friday. Celsion has a one year low of $1.24 and a one year high of $7.56.
Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.17. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%. research analysts predict that Celsion will post -2.46 EPS for the current year.
An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new position in Celsion Co. (NASDAQ:CLSN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.01% of the company’s stock.
WARNING: This report was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thestockobserver.com/2018/02/05/celsion-clsn-lowered-to-strong-sell-at-valuengine.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.